Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Eve Lamar

Nurse Practitioner Evansville, IN Nurse Practitioner

NPI 1518430263 CMS profile 10511832

520 Mary St Ste 230, Evansville, IN 47701

Open in the dashboard

General payments

$4,993

261 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Eve Lamar of Evansville, IN is reported in the CMS Open Payments database as having received $4,993 across 261 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,156 33
2024 General $507 28
2023 General $902 51
2022 General $844 54
2021 General $1,584 95

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eve Lamar
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Eve Lamar were reported at $1,156. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Eve Lamar Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,584 $135 $40–$426 $132
2022 $844 $152 $48–$470 $149
2023 $902 $166 $54–$529 $160
2024 $507 $173 $55–$556 $164
2025 $1,156 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $1,039 81 payments
  2. Abiomed $874 15 payments
  3. Janssen Pharmaceuticals, Inc $726 48 payments
  4. E.R. Squibb & Sons, L.L.C. $369 26 payments
  5. Pfizer Inc. $317 18 payments
  6. Atricure, Inc. $315 4 payments
  7. Novartis Pharmaceuticals Corporation $284 21 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $198 10 payments
  9. AstraZeneca Pharmaceuticals LP $177 6 payments
  10. Amgen Inc. $120 5 payments
  11. Other $574 27 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,624 257 payments
  2. Travel and Lodging $369 4 payments
Products named General payments · program years 2021–2025
  1. LifeVest $1,039 81 payments
  2. XARELTO $726 48 payments
  3. EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX $315 4 payments
  4. ELIQUIS Cardiovascular;Metabolic Disease $242 14 payments
  5. CAMZYOS $207 9 payments
  6. ENTRESTO $168 12 payments
  7. ELIQUIS Cardiovascular $161 17 payments
  8. FARXIGA $150 4 payments
  9. JARDIANCE $148 8 payments
  10. Repatha $120 5 payments
  11. Other $1,366 64 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$2,896

Medicare's payments for the services billed

Medicare patients

37

Average age 77

Services billed

41

18 women, 19 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
Ischemic heart disease 75%
Chronic kidney disease 75%
Arthritis 68%
Atrial fibrillation 62%
Diabetes 57%
COPD 49%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $43
  • PFIZER INC. $40
$83 — —
XARELTO
  • Janssen Pharmaceuticals, Inc $70
$70 — —
VERQUVO
  • Merck Sharp & Dohme Corporation $36
$36 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $24
$24 — —
NURTEC ODT
  • PFIZER INC. $6
$6 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

261 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record